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Abstract
Background: Mast cells are known to accumulate at sites of inflammation and upon activation to
release their granule content, e.g. histamine, cytokines and proteases. The secretory leukocyte
protease inhibitor (SLPI) is produced in the respiratory mucous and plays a role in regulating the
activity of the proteases.
Result: We have used the HMC-1 cell line as a model for human mast cells to investigate their
effect on SLPI expression and its levels in cell co-culture experiments, in vitro. In comparison with
controls, we found a significant reduction in SLPI levels (by 2.35-fold, p < 0.01) in a SLPI-producing,
type II-like alveolar cell line, (A549) when co-cultured with HMC-1 cells, but not in an HMC-1-
conditioned medium, for 96 hours. By contrast, increased SLPI mRNA expression (by 1.58-fold, p
< 0.05) was found under the same experimental conditions. Immunohistochemical analysis revealed
mast cell transmigration in co-culture with SLPI-producing A549 cells for 72 and 96 hours.
Conclusion: These results indicate that SLPI-producing cells may assist mast cell migration and
that the regulation of SLPI release and/or consumption by mast cells requires interaction between
these cell types. Therefore, a "local relationship" between mast cells and airway epithelial cells
might be an important step in the inflammatory response.
Background
The inflammatory process in the respiratory airways
includes the release of several mediators such as chemoat-
tractants, cytokines and proteinases that regulate the
adhesion of molecules, and the processes of cell migra-
tion, activation and degranulation. The characteristic
destruction of tissue in inflammatory diseases is to a large
extent mediated by an excess of neutral serine proteinases
and matrix metalloproteinases (MMP) [1–4]. The serine
proteinases also contribute to the activation of MMPs,
which are typically released in a latent form [5]. Therefore,
the regulation of proteolytic enzyme activity in the respi-
ratory airways by endogeneous inhibitors is a prerequisite
for the maintenance of tissue integrity, and for the repair
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of tissue damage. Proteinase inhibitors that provide pro-
tection against the extracellular activity of serine protein-
ases include alpha1-antitrypsin (AAT), secretory leukocyte
proteinase inhibitor (SLPI) and elafin/skin–derived anti-
leukoproteinase (SKALP). Whereas AAT is produced
mainly by the liver and reaches the tissues via passive dif-
fusion [6], SLPI and elafin/SKALP are produced locally
[7–12]
SLPI is found in considerable amounts in nasal, bronchial
and cervical mucous, in saliva, and in seminal fluid
[7,9,13–16]. There is increasing evidence that SLPI has
numerous functions that are not related to its protease-
inhibitory activity. SLPI is a non-glycosylated, hydropho-
bic, cationic 12 kDa protein, consisting of two homolo-
gous cystein-rich domains of 53 and 54 amino acids [17].
The carboxyl-terminal domain of SLPI manifests inhibi-
tory activities against chymotrypsin, trypsin, granulocyte
and pancreatic elastase, cathepsin G and mass cell chy-
mase [18–22], whereas anti-inflammatory, anti-bacterial
and anti-fungal activities appear to reside in its amino-ter-
minal domain [23,24]. SLPI is shown to reduce LPS-
induced TNFα production in the macrophage cell line
[25,26], to suppress the production of prostaglandin E2
and metalloproteinase in monocytes [27], and also to
antagonize up-regulation of nuclear transcription factor
(NF-κB) activation [28]. Lentsch and co-workers have
demonstrated that SLPI attenuates the acute inflamma-
tory response caused by the deposition of IgG immune
complexes in the lungs [29]. In addition, Ashcroft and
associates found that SLPI might play a crucial role in
wound healing [30]. Recently SLPI has also been shown to
inhibit HIV-1 replication in cultured human monocytes
[23]. The up-regulation of SLPI by bacterial lipopolysac-
charides, and cytokines such as TNFα and IL-1β, com-
bined with a broad spectrum antibiotic activity against
gram-positive and gram-negative bacteria, suggest it to be
a potent anti-microbial "defensin-like" peptide produced
by the lungs. States of impaired healing are characterized
by excessive proteolysis and often bacterial infection,
leading to the hypothesis that SLPI may also have a role in
this process.
Historically, SLPI was first purified from secretions of
patients with chronic, obstructive pulmonary disease and
cystic fibrosis [18], and it was suggested that SLPI being a
major anti-elastase inhibitor of the bronchi, is an impor-
tant molecule for protecting the respiratory epithelium
[13,15]. In contrast to α1-antitrypsin, SLPI blocks elastin-
bound elastase in the alveolar walls, which might also
protect against the development of emphysema [31]. The
interaction between SLPI and elastase is reversible, proba-
bly facilitating the transfer of neutrophil elastase to α1-
antitrypsin [32]. It is important to point out that neu-
trophil elastase has been found to increase SLPI mRNA
expression in lung epithelial cells in vitro, but this increase
in SLPI expression was accompanied by a decrease in SLPI
protein release [33]. The local induction of SLPI might be
important to break the cycle of inflammation. However
the mechanisms involved in the regulation of SLPI expres-
sion and release still remain to be elucidated. It has been
shown that SLPI is up-regulated by pro-inflammatory
stimuli including LPS, TNFα, IL-6 and IL-1β,  in vitro
[25,26,34,35]. Corticosteroids have also been found to
enhance SLPI mRNA levels in airway epithelial cells lead-
ing to the suggestion that antiinflammatory effects of cor-
ticosteroids may be related to the stimulated SLPI levels
[36]. The demonstration that neutrophil defensins
increase SLPI release from the bronchial epithelial cells
supports the idea that leukocytes play a prominent role in
the regulation of SLPI production [37].
Contradictory results have been presented concerning the
levels of SLPI during allergic rhinitis in antigen-challenged
atopic subjects. For example, lower SLPI levels were found
in the bronchial secretions of asthma patients [38]. Other
studies indicated that levels of SLPI are also lower in nasal
secretion of allergic rhinitis patients compared to healthy
controls. After allergen challenge SLPI seems to decrease
in the nasal secretions in atopic subjects, which probably
indicates mucosal damage [39]. However, the question
why SLPI levels is decreased during certain allergic reac-
tions, still remains to be answered.
Histamine release from HMC-1 cells Figure 1
Histamine release from HMC-1 cells. Histamine release was 
measured at different time points: 0, 3, 6 and 24 h and calcu-
lated as a percent of the total cellular histamine content. 
Each point represents mean ± S.D. of five or six separate 
experiments. Histamine release increases from 4 % to 25 % 
over time (p < 0.05).
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Allergic inflammation, including rhinitis, asthma, anaph-
ylaxis and urticaria are all disorders associated with mast
cell activation [40]. Mast cells are multifunctional cells
capable of secreting a wide variety of cytokines, chemok-
ines and growth factors [41,42]. The mediators released
by mast cells can independently, and in synergy with mac-
rophage- and T-cell-derived cytokines, induce much of the
inflammatory pathology and serve to stimulate a complex
immune response [43,44]. Mast cells are the primary ini-
tiating cell of IgE-mediated hypersensitivity. Allergen
binding to, or the cross-linking of IgE on the surface of
mast cells, which is bound to the high affinity IgE-recep-
tor, leads to the rapid release of inflammatory mediators
that further provoke a profound immunological and
inflammatory process. There are indications that SLPI can
inhibit IgE-mediated histamine release from rodent and
human nasal mucosa mast cells [45,46]. SLPI may also
counterbalance the proteolytic activities caused by pro-
tease leakage from the cells [47]. Mast cell and leukocyte
serine proteinases are shown to be elevated in the airways
of asthmatic patients [40,48]. Individuals with reduced
anti-proteinase activity as a result of AAT deficiency, have
an increased propensity to develop asthma [49,50].
Together, these findings indicate that proteinase-antipro-
teinase imbalance in the airways contributes to the patho-
physiological responses in the airways. Because SLPI
provides a potent, broad-spectrum inhibitory activity
against mast cell and leukocyte serine proteinases, this
protein is suggested to be an effective protector against
antigen-induced inflammatory responses in the airways.
The purpose of this study is to further elucidate how local
SLPI levels may be influenced during mast cell interaction
with epithelial cells. A co-culture model was used, in
which we studied mast cells HMC-1 affect on SLPI levels
released from the type II alveolar cell line (A549) derived
from human lung carcinoma.
Results
Mast cell characterisation
Most studies performed on the mechanisms of the mast
cell degranulation are based on the release of histamine.
Histamine is electrostatically linked to the protein heparin
complex in a manner, which allows it to be released very
easily. As shown in figure 1, a spontaneous histamine
release from HMC-1 cells consistently increases with incu-
bation time (up to 24 h) from 4% to 25% relative to the
total cellular histamine content. Continues cell incuba-
tion (up to 96 h) showed no further changes in histamine
release (data not shown). In addition, the supernatants
from the HMC-1 cells alone did not contain SLPI after cell
culture for 24 and 48 h, and only trace amounts of SLPI
are detected after 72 and 96 h of incubation (Table 1). The
ability of HMC-1 cells to express SLPI was also confirmed
by immunohistochemical analysis (Fig. 2A and 2B).
Cell co-culture experiments
Epithelium cells, A549, cultured alone for 24, 48, 72 and
96 h increased the SLPI release from 6.7 ± 0.26 to 38.8 ±
0.98 pg/ml (Table 1). Next, we studied the effect of mast
cells on SLPI levels by using a transmigration model in
which mast cells HMC-1 migrated across the topside of
the transwell filter towards the A549 cells. The results
obtained with this model show that, during the first 48 h
of cell co-culture, mast cells did not migrate into the lung
epithelium cell culture (Fig. 3A). However, as shown in
figure 3B, cell co-culture for 72 h resulted in a slight mast
cell transmigration as indicated by the presence of immu-
noreactive HMC-1 cells among the A549 cells. This was,
furthermore, confirmed by the co-culture of these cells for
96 h after which a large number of immunoreactive mast
cells was detected among the A549 cells (Fig. 3C). It
should be pointed out that HMC-1 cells showed no ability
to transmigrate through a "blank" transwells. Moreover,
cells which had not migrated into the polyester mem-
brane inserts displayed immunoreactivity to tryptase for
all incubation times, from 24 to 96 h, showing that under
the chosen experimental conditions mast cells preserved
Table 1: Time dependent SLPI release from the mast cells, HMC-1, and type II epithelium cells, A549, cultured alone
Incubation time HMC-1 cells A549 cells
(h) SLPI (pg/ml) SLPI (pg/ml)
Mean SD Mean SD
24 - ± - 6.7 ± 0.26
48 - ± - 14.5 ± 0.9
72 0.17 ± 0.07 14.4 ± 1.5
96 0.2 ± 0.06 38.75 ± 0.98
*) mean and standard deviation of 2 experimentsCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/14
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their capacity to differentiate (not shown). We further
examined the effect of mast cell trans-migration on the
amount of SLPI released by the A549 cells into cell culture
media. Only a slight decrease in SLPI levels was observed
during 72 h of cell co-culture compared to the SLPI-pro-
ducing cells alone (Fig. 4). However, when cells were co-
cultured for 96 h a significant decrease in SLPI levels was
found. As shown in figure 3, SLPI levels decline by 2.35-
fold (p < 0.01) in the presence of mast cells relative to the
A549 cells alone.
Effects of conditioned media on SLPI levels
In the next series of experiments we aimed to investigate
if concentration of SLPI can be influenced by the incuba-
tion of A549 cells with HMC-1-conditioned medium for
various time periods (from 24 to 96 h). In this case, a
medium collected from mast cells at different time points
was added to the A549 cells and allowed to act for 24, 48,
72 and 96 h. As shown in Figure 5, the culture of
epithelium cells in the mast cell-media caused no changes
in SLPI levels.
SLPI mRNA expression by A549 cells
To determine whether the decrease of SLPI levels in co-
culture with mast cells involves changes in SLPI mRNA
expression in A549 cells, we monitored the SLPI mRNA/
β-Actin ratio in A549 cells alone and in co-culture over the
period of 24 to 96 h. As shown in figure 6, the levels of
SLPI mRNA expression were relatively unchanged when
A549 cells were cultured alone. By contrast, increased SLPI
mRNA levels were observed in co-culture experiments
after 96 h (1.58-fold, p < 0.05) compared to 24 or 48 h.
Under the same experimental conditions, we also exam-
ined whether addition of conditioned medium from
HMC-1 cells effects SLPI mRNA expression in same way.
Consistent with our earlier observations (Fig. 5) showing
that A549 cells incubated with conditioned medium from
mast cells did not change SLPI protein levels, we found
that under these experimental conditions SLPI mRNA lev-
els are not changed either (data not shown).
Discussion
Mast cells are widely distributed within the connective tis-
sue, with a preferential localization adjacent to the small
blood vessels. They play a central role in inflammatory
and allergic reactions, and are involved in tissue
remodelling during wound healing [40]. The mast cell
responses involve the ingestion and killing of adherent
substances, unlike that of traditional phagocytic cells.
Concomitant with this endocytic activity, inflammatory
mediators are released by the mast cells.
Mast cells constitute a heterogeneous group of cells con-
taining several proteases, i.e. tryptase, carboxypeptidase,
cathepsin G and chymase [51]. Mainly there are two kinds
of mast cells, those in the connective tissue (MCTC) and
those in the mucosa (MCT). They differ in protease con-
tent, MCTC cells contain tryptase and chymase, whereas
MCT cells contain only tryptase. The MCTC cells are pre-
dominant in the nasal mucosa while MCT cells are more
prevalent in the peripheral lung tissue. Mast cells have
also been found to interact with different types of cells,
including fibroblasts, endothelial cells, lymphocytes,
macrophages, neutrophils, eosinophils, nerve cells and
cancer cells [40,43,52,53]. However, the adhesive
Localisation of SLPI in HMC-1-mast cells. A, the control  slides were incubated with specific antiserum previously  adsorbed with SLPI (1/500) and no positive staining for  HMC-1 cells was found (original magnification × 500) Figure 2
Localisation of SLPI in HMC-1-mast cells. A, the control 
slides were incubated with specific antiserum previously 
adsorbed with SLPI (1/500) and no positive staining for 
HMC-1 cells was found (original magnification × 500). B, 
HMC-1 cells stained with polyclonal goat-anti-SLPI antibody 
(1/500) show immunoreactivity for SLPI (original magnifica-
tion × 500).
Mast cell HMC-1 migration towards the lung type II epithe- lium cells, A549 Figure 3
Mast cell HMC-1 migration towards the lung type II epithe-
lium cells, A549. Specimens stained with a mouse anti-human 
mast cell 229; kidney juxtaglomerular CE diluted 1/5000 
show immunoreactivity for HMC-1 mast cells. A, HMC-1 are 
not detected among the lung carcinoma cells after 24 h of 
cell co-culture. B and C, Solitary cells and a large number of 
cells can be detected after 72 and 96 hours of cell co-culture, 
respectively. Original magnification × 200. Mast cell immuno-
reactivity indicated by arrow.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/14
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mechanisms initiating cell-cell interaction and the conse-
quences of this are not well understood.
The present study was designed to investigate the adher-
ence of mast cells, HMC-1, to the cell line A549, which
represents epithelial cells within the respiratory tract, and
to investigate the effects of this cell-cell interaction on
SLPI levels.
The mast cell line HMC-1 is known to express a number
of β1- and α-integrins as well as other receptors which per-
mit the binding of these cells to the extracellular matrix
compounds [53–55]. The factors that stimulate mast cell
migration still remain largely undefined, although recent
reports have implicated the transforming growth factor-β
family (TGFβ) as the potential candidate for acting as
mast cell chemotaxin, recruiting mast cells into inflamma-
tory reactions [56]. In accordance with other studies, we
found that HMC-1 mast cells growing in suspension
adhere efficiently and spread on top of cell monolayers, in
our case on top of A549 cells. After 72 h of HMC-1/A549
co-culture, solitary HMC-1 cells were detected among the
A549 cells, while after 96 h a large number of mast cells
was found to be adhering to the A549 cells. The mainte-
nance of HMC-1 cell maturity was verified by the tryptase
immunoreactivity each of the periods of cell culture.
The role of mast cells as primary effector cells in IgE-
dependent, immediate hypersensitivity is well established
[57]. The discovery that mast cells can release a wide
variety of immune mediators, including proteases,
cytokines, chemokines and growth factors, suggests an
additional role of mast cells in modulating late-phase
reactions and other chronic inflammatory processes
[40,42]. Here we also demonstrate by immunocytochem-
istry that HMC-1 mast cells are SLPI-positive, and trace
amounts of SLPI were found in the cell culture superna-
tants collected after 72 and 96 h of culture. Although the
amount of SLPI released by few activated mast cells had
no importance for the present study, this observation still
extends earlier findings showing that SLPI and other chy-
mase inhibitors, i.e. α1-antichymotrypsin and α1-antit-
rypsin are present in stimulated mast cells and protect the
microenvironment against chymase activity [47]. Previ-
ously it has been shown that chymase degranulates mast
cells, induces histamine release and an increase in SLPI
concentration [58]. Neutrophil elastase was also found to
increase SLPI transcript levels in primary and transformed
human airway epithelial cells in a time- and dose-depend-
ent manner [34,36]. These observations suggest that the
sensitive regulation of anti-proteases, such as SLPI, in rela-
tion to local levels of proteases, may play an important
role in minimising tissue destruction.
Effects of mast cells HMC-1 on the ability of the A549 cells  to release SLPI Figure 4
Effects of mast cells HMC-1 on the ability of the A549 cells 
to release SLPI. The SLPI release from the A549 cells was 
decreased in co-cultured with HMC-1 cells, compared to the 
A549 cells alone (p < 0.006). The most pronounced fall in 
SLPI production was observed after 96 hours of cell co-cul-
ture (**p < 0.01). Each point represents mean of six or five 
separate experiments.
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Effects of HMC-1-conditioned medium on SLPI levels in A549  cells Figure 5
Effects of HMC-1-conditioned medium on SLPI levels in A549 
cells. Medium from HMC-1 cells cultured for 0, 3, 6, 8 and 24 
h was used to incubate A549 cells for various time periods 
(from 24 to 96 h). The mast cell-media caused no changes in 
SLPI levels. Each point represents mean of three independent 
experiments
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With these results as a background we have further inves-
tigated the effects of mast cells on the capacity of epithe-
lial-presenting cells, A549, to express and release SLPI. In
our experimental model, SLPI-producing epithelial cells
were cultured for determined time points in conditioned
media obtained from mast cells or in co-culture with mast
cells. By using this approach, we were able to show that
under cell co-culture conditions SLPI levels in cell culture
media are gradually decreased, although the expression of
mRNA SLPI increases. A significant diminition in SLPI lev-
els (by 2.35-fold) was observed after 96 h of cell co-cul-
ture, although the SLPI mRNA was up-regulated (by 1.58-
fold). In contrast, the A549 cell culture in the mast cell
conditioned medium for the time periods chosen had no
influence either on SLPI protein levels or on SLPI mRNA
expression. By measuring histamine release and tryptase
activity in media from mast cells cultured alone for up to
96 h, we were able to show that these cells are not acti-
vated. Histamine levels plateaued after 24 h of cell culture
which explains why the conditioned media collected from
mast cells and added to the SLPI producing cells (A549)
had no effect on SLPI levels.
Based on these findings one can conclude that mast cells
exert an inhibitory effect on SLPI levels only when they are
in close contact with SLPI-producing, A549, cells. Since
our primary goal was to find out if mast cell interaction
with epithelial cells by itself can induce expression of SLPI
and reduce its levels in media, we specifically did not
investigate mast cell exogenous activation under these
conditions. This indirectly shows that SLPI is either con-
sumed (for example degraded or in complex with
enzymes) or its release is inhibited. Studies on this point
are in progress in our laboratory.
Recently, van Wetering and co-workers have shown that
neutrophil elastase increases SLPI mRNA expression,
while it decreases SLPI protein release, in vitro [37]. On the
other hand, studies by Hill and co-workers, have indicated
that SLPI concentration does not decrease until the
elastase activity of the samples is in excess of 50 nM [48].
The relationship between SLPI and elastase is therefore
found not to be a simple linear, indicating that a certain
amount of elastase and/or other enzymes is needed in
order to induce epithelial damage or interfere with epithe-
lial cell metabolism resulting in a decreased SLPI secretion
[12,32,34].
SLPI levels were found to be decreased in nasal secretion
after antigen challenge in vivo [39] as well as in bronchial
alveolar lavage obtained from asthmatics compared to
healthy subjects [38]. In the airways of allergic patients,
mast cells are found in the close proximity of airway epi-
thelial cells, which may indicate that mast cells and epi-
thelial cells influence each other's properties. Together,
previous findings, that SLPI levels are lower in inflamma-
tory loci in airways and data from our experimental
model, that co-culture of mast cells with SLPI-producing
epithelial-like, A549, cells, results in decreased SLPI levels
in cell co-culture media suggest that decrease in local anti-
protease activity might sustain mucosal damage in reac-
tions in which mast cells are participating.
Conclusion
Airway inflammation, present in asthma, bronchitis, and
bronchiectasis, is characterised by the presence of acti-
vated inflammatory cells. The proteinases, presumably
leaking from the cells during their migration from the
blood into the extracellular space, can be detrimental to
the connective tissue. Proteinase inhibitors, such as SLPI,
produced locally in the airway epithelium, are thought to
be important in minimising proteolytic damage during
inflammation. On the other hand, proteinases may also
play a role in the regulation of the antiproteinase profile
at the epithelial site. Thus, the auto-regulatory loop
observed, namely that the up-regulation of SLPI mRNA
parallels apparent down-regulation of the levels of the
SLPI in the mast/epithelial like cell, A549, co-culture
model, will need further investigations. An understanding
of the mechanisms involved in SLPI protein expression,
release and consumption may provide important knowl-
edge regarding the dynamics of the regulation of the pro-
tease/antiprotease systems.
SLPI mRNA expression by lung epithelium, A549, cells.  Increased SLPI mRNA levels in co-culture experiments were  observed after 96 h (* p < 0.05), compared to 24 and 48  hours Figure 6
SLPI mRNA expression by lung epithelium, A549, cells. 
Increased SLPI mRNA levels in co-culture experiments were 
observed after 96 h (* p < 0.05), compared to 24 and 48 
hours. No change in SLPI mRNA levels was found when lung 
carcinoma cells were cultured alone.
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Materials and Methods
Cell cultures
The human mast cells HMC-1, established from a patient
with mast cell leukaemia, were obtained from Dr J.H. But-
terfield, Mayo Clinic, Rochester, MN, USA [59] The cells
were cultured in 75 cm2 flasks in Iscove's modified Dul-
becco's medium (Gibco BRL, Paisly, UK) supplemented
with 10% (v/v) iron-supplemented fetal calf serum (FCS)
(Gibco BRL), 1.2 mM α-thioglycerol (Sigma, St Louis,
MO, USA), 100 IU/ml penicillin, 100 µg/ml streptomycin
and 2.5 µg/ml amphotericin B and fungizone (Gibco
BRL), in humidified air with 5% CO2, at 37°C. At conflu-
ence, the cells were centrifuged at 2000 g for 5 min,
washed in PBS, re-suspended in cell culture medium and
counted in a Bürker chamber. The viability of the HMC-1
cells was ≥ 95%.
SLPI producing a type-II alveolar cell line (A549) derived
from human lung carcinoma, was cultured in RMPI-1640
medium supplemented with 10% FCS, 100 IU/ml penicil-
lin, 100 µg/ml streptomycin and 2.5 µg/ml amphotericin
B and fungizone at 37°C in an atmosphere of humidified
air saturated with 5% CO2. The cells were subcultured
every 4–5 days by tripsinization and were used for experi-
ments after reaching confluence.
Human type II lung epithelium cells (A549) and HMC-1 co-
culture models
Epithelium cells (A549) were cultured in the lower com-
partment of the cell co-culture plates (Nunc, Wiesbaden,
Germany) to obtain confluent monolayers. A constant
amount of HMC-1 cells (106 cells/ml) was seeded on
fibronectin-coated polycarbonate transwell filters (pore
size 3 µm and 12 mm in diametre). The cells were co-cul-
tured in an Iscove's modified Dulbecco's medium for 24,
48, 72 and 96 h. The cell viability was analysed after 96 h
of cell co-culture by a trypan blue staining, and was found
to be 90 % and 95% for the mast cells and for the lung
epithelium cells, respectively. For the controls, A549 cells
and mast cells were cultured separately in co-culture
plates under the same experimental conditions as
described above. The experiments were repeated six times.
SLPI expression by A549 cells alone and in co-culture 
models
Total RNA was isolated and quantified from A549 cells
cultured alone and in co-culture. The cells were lysed in
1.5 ml lyses buffer (4 M guanidinum thiocyanate, 25 mM
sodium citrate (pH 7), containing 0.5% antifoam A and
100 mM 2-mercaptoethanol). Total RNA was extracted
using a single-step method based on acid-guanidinum
thiocyanate-phenol-chloroform extraction described by
Chomczynski and Sacchi [60]. The total RNA yield was
quantified at 260 and 280 nm. The transcript levels of
SLPI and β-actin were evaluated by slot blot, using a
Magnagraph (MSI) nylon membrane according to the
manufacturer's instructions. Briefly, 5 µg of total RNA was
mixed with 100 µl of dilution buffer containing 7.4% for-
maldehyde-7 and SSPE (150 mM sodium chloride, 10 nM
sodium phosphate and 1 mM EDTA), denatured for 5 min
in boiling water, cooled very fast (0°C) for 2 min and
loaded onto the nylon membrane. SLPI mRNA was
detected with a cocktail of an equimolar mixture of three
single stranded oligonucleotide probes (British Biotech-
nology Products LTD, Oxon, UK). The probes were based
on the antisense sequence and modified at the 5' end with
digoxigenin. The digoxigenin-labelled β-actin probe was
purchased from Roche, catalogue number 1498045. The
blots were exposed to Kodak XAR-5 X-ray film (Sigma
Chemical, St. Louise, MO). Autoradiographs were ana-
lysed using the Fuij film LAS-100, Luminescent Image
analyser and Image reader macintosh version 1.0 was
used to determine the densitometric units for both SLPI
and  β-actin. The data represent the mean SLPI/β-actin
ratio.
SLPI and histamine quantification assays
SLPI was quantified in the cell supernatants obtained
from each experimental condition. Analyses of SLPI were
performed by using the quantitative sandwich ELISA kit
according to the manufacture recommendations (R&D
systems, Inc, USA). The minimum detectable dose of SLPI
was less than 25 pg/ml. The mast cell degranulation was
verified by the amount of histamine released. Histamine
was quantified in the supernatants obtained from the
mast cells cultured alone after the various incubation time
points. Histamine was measured by a sensitive radioen-
zyme assay based on the conversion of histamine to [3H]
methylhistamine in the presence of the enzyme histamine
– N-methyltransferase using S-adenosyl-L-[methyl-3H]
methionine as the methyl donor, using a commercial
radioimmunoassay (RIA)-kit (Immunotech, KEMILA, Sol-
lentuna, Sweden). Histamine secretion is expressed as a
percentage of total cellular content (cell lysate plus spon-
taneous release) and is corrected for spontaneous release.
Immunohistochemistry
To monitor the differentiation of the mast cells we stained
cells for tryptase after the various incubation times of 24,
48, 72 and 96 h. The mast cells were also stained for SLPI
in order to eliminate the possibility that these cells them-
selves produce significant amounts of this protein. To
confirm mast cell migration, the lung carcinoma cells, co-
cultured with mast cells for various time periods, were
immunohistochemically stained with a monoclonal anti-
mast cell antibody.
To block unspecific staining, the slides were incubated
with 5% or 10% of normal horse serum for 20 minutes at
room temperature. Polyclonal goat-anti-SLPI antibodyCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/14
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(produced at our laboratory) was used as primary anti-
body at dilutions of 1/500 and 1/1000, a monoclonal
mouse anit-tryptase antibody, Mab 1254 (DAKO, Glos-
trup, Denmark) diluted 1/1000 was added and allowed to
react for 90 min at room temperature. To identify
migrated mast cells, a mouse anti-human mast cell 229;
kidney juxtaglomerular CE (Swant, Switzerland) diluted
1/5000 was applied under the conditions described
above. Control slides were incubated with the buffer or
non-immunised mouse IgG (negative control), instead of
primary antibody. The slides were washed and the second
labelled antibody was applied and left for 30 min at room
temperature. The slides were incubated with biotinylated
rabbit anti-goat IgG antibody (5 mg/ml buffer) and then
incubated with avidin DH biotinylated horseradish per-
oxidase (ABC) complexes. After this, the slides were
washed again and stained with 0.06% 3,3'-diamino-ben-
zidine-tetrahydrochloride (DAB) for 20 min and
mounted. In addition, the control slides were incubated
with specific antiserum previously adsorbed with SLPI.
Human type II lung epithelium cells, A549, cultured in 
HMC-1-conditioned medium
Lung epithelium, A549, cells and mast cells were cultured
and prepared as described above. A549 cells were re-
seeded into the six-well plates and grown till confluence.
The supernatants collected from the mast cells after differ-
ent periods of time (0, 3, 9 and 24 h) were added to the
A549 cells for a further incubation of 24, 48, 72 and 96 h.
A549 cell controls were cultured in a cell growth medium
for the same length of time. SLPI levels were measured in
the supernatants collected from the HMC-1 cells before
and after addition to the lung carcinoma cells. These
experiments were repeated four times.
Statistics
Regression coefficients were calculated for each SLPI
release curve from each of the experiments. The
hypothesis i.e. the differences in regression coefficient
were tested with a non-parametric Wilcoxon's paired rank
sum test. The Mann-Whitney U-test was calculated on the
results of 24, 48, 72 and 96 h of cell culture. Results are
expressed as the mean ± SD of at least four to six inde-
pendent experiments. P values exceeding 0.05 were con-
sidered not significant.
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SLPI, secretory leukocyte protease inhibitor; MMP, matrix
metalloproteinases; AAT, alpha1-antitrypsin; IL, inter-
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Authors' contributions
HC and NM, carried out the cell culture experiments and
immunohistochemistry and drafted the manuscript, SJ,
performed the statistical analysis and presentation of the
data, described and interpreted data, UW, participated in
study design, data evaluation and coordination.
Acknowledgements
This study was supported by grants from the Swedish Medical Research 
Council (3910), the foundations of Alfred Österlund and the Medical Foun-
dations of University Hospital Malmö and the Medical Faculty.
References
1. Janoff A: Proteases and lung injury. A state-of-the-art
minireview. Chest 1983, 83:54S-58S.
2. Janoff A: Elastase in tissue injury. Annu Rev Med 1985, 36:207-16.
3. Ohbayashi H: Matrix metalloproteinases in lung diseases. Curr
Protein Pept Sci 2002, 3:409-21.
4. Tetley TD: Macrophages and the pathogenesis of COPD. Chest
2002, 121:156S-159S.
5. Finlay GA, Russell KJ, McMahon KJ, D'Arcy M, Masterson EJB, Fit-
zGerald MX and O'Connor CM: Elevated levels of matrix metal-
loproteinases in bronchoalveolar lavage fluid of
emphysematous patients. Thorax 1997, 52:502-6.
6. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC,
Vaughan L and Boswell DR: Structure and variation of human
alpha 1-antitrypsin. Nature 1982, 298:329-34.
7. Fryksmark U, Ohlsson K, Polling A and Tegner H: Distribution of
antileukoprotease in upper respiratory mucosa. Ann Otol Rhi-
nol Laryngol 1982, 91:268-71.
8. Mooren HW, Kramps JA, Franken C, Meijer CJ and Dijkman JA:
Localisation of a low-molecular-weight bronchial protease
inhibitor in the peripheral human lung. Thorax 1983, 38:180-3.
9. Ohlsson M, Fryksmark U, Polling A, Tegner H and Ohlsson K: Local-
ization of antileukoprotease in the parotid and the sub-
mandibular salivary glands. Acta Otolaryngol 1984, 98:147-51.
10. Kuijpers AL, Alkemade HA, Schalkwijk J and van de Kerkhof PC: Top-
ographic relation between skin-derived antileukoproteinase
(SKALP) and leukocyte elastase in a case of annular pustular
psoriasis. Acta Derm Venereol 1995, 75:110-3.
11. Mihaila A and Tremblay GM: Human alveolar macrophages
express elafin and secretory leukocyte protease inhibitor. Z
Naturforsch [C] 2001, 56:291-7.
12. Saitoh H, Masuda T, Shimura S, Fushimi T and Shirato K: Secretion
and gene expression of secretory leukocyte protease inhibi-
tor by human airway submucosal glands. Am J Physiol Lung Cell
Mol Physiol 2001, 280:L79-87.
13. Ohlsson K and Tegner H: Inhibition of elastase from granulo-
cytes by the low molecular weight bronchial protease
inhibitor. Scand J Clin Lab Invest 1976, 36:437-45.
14. Ohlsson K, Bjartell A and Lilja H: Secretory leucocyte protease
inhibitor in the male genital tract: PSA-induced proteolytic
processing in human semen and tissue localization. J Androl
1995, 16:64-74.
15. Tegner H: Quantitation of human granulocyte protease inhib-
itors in non-purulent bronchial lavage fluids. Acta Otolaryngol
1978, 85:282-9.
16. Fritz H: Human mucus proteinase inhibitor (human MPI).
Human seminal inhibitor I (HUSI-I), antileukoprotease
(ALP), secretory leukocyte protease inhibitor (SLPI).  Biol
Chem Hoppe Seyler 1988, 369(Suppl):79-82.
17. Thompson RC and Ohlsson K: Isolation, properties, and com-
plete amino acid sequence of human secretory leukocyte
protease inhibitor, a potent inhibitor of leukocyte elastase.
Proc Natl Acad Sci U S A 1986, 83:6692-6.
18. Hochstrasser K, Reichert R, Schwarz S and Werle E: [Isolation and
characterisation of a protease inhibitor from human bron-
chial secretion]. Hoppe Seylers Z Physiol Chem 1972, 353:221-6.
19. Eisenberg SP, Hale KK, Heimdal P and Thompson RC: Location of
the protease-inhibitory region of secretory leukocyte pro-
tease inhibitor. J Biol Chem 1990, 265:7976-81.
20. Renesto P, Balloy V, Kamimura T, Masuda K, Imaizumi A and Chignard
M:  Inhibition by recombinant SLPI and half-SLPI (Asn55-
Ala107) of elastase and cathepsin G activities: consequence
for neutrophil-platelet cooperation.  Br J Pharmacol 1993,
108:1100-6.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/14
Page 9 of 9
(page number not for citation purposes)
21. Masuda K, Kamimura T, Kanesaki M, Ishii K, Imaizumi A, Sugiyama T,
Suzuki Y and Ohtsuka E: Efficient production of the C-terminal
domain of secretory leukoprotease inhibitor as a thrombin-
cleavable fusion protein in Escherichia coli. Protein Eng 1996,
9:101-6.
22. Pemberton AD, Huntley JF and Miller HR: Differential inhibition of
mast cell chymases by secretory leukocyte protease
inhibitor. Biochim Biophys Acta 1998, 1379:29-34.
23. Shugars DC, Sauls DL and Weinberg JB: Secretory leukocyte pro-
tease inhibitor blocks infectivity of primary monocytes and
mononuclear cells with both monocytotropic and lymphocy-
totropic strains of human immunodeficiency virus type I. Oral
Dis 1997, 3(Suppl 1):S70-2.
24. Tomee JF, Koeter GH, Hiemstra PS and Kauffman HF: Secretory
leukoprotease inhibitor: a native antimicrobial protein pre-
senting a new therapeutic option? Thorax 1998, 53:114-6.
25. Jin FY, Nathan C, Radzioch D and Ding A: Secretory leukocyte
protease inhibitor: a macrophage product induced by and
antagonistic to bacterial lipopolysaccharide.  Cell 1997,
88:417-26.
26. Jin F, Nathan CF, Radzioch D and Ding A: Lipopolysaccharide-
related stimuli induce expression of the secretory leukocyte
protease inhibitor, a macrophage-derived lipopolysaccha-
ride inhibitor. Infect Immun 1998, 66:2447-52.
27. Zang Y, De Witt DL, McNeely TB, Wahl SM and Wahl LM: Secre-
tory leukocyte protease inhibitor suppresses the production
of monocyte prostaglandin H synthase-2, prostaglandin E2,
and matrix metalloproteases. J Clin Invest 1997, 99:894-900.
28. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V
and Ward PA: Inhibition of NF-kappaB activation and aug-
mentation of IkappaBbeta by secretory leukocyte protease
inhibitor during lung inflammation.  Am J Pathol 1999,
154:239-47.
29. Ward PA and Lentsch AB: Endogenous regulation of the acute
inflammatory response. Mol Cell Biochem 2002, 234–235:225-8.
30. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-
Wild T, Hale-Donze H, McGrady G, Song XY and Wahl SM: Secre-
tory leukocyte protease inhibitor mediates non-redundant
functions necessary for normal wound healing. Nat Med 2000,
6:1147-53.
31. Bruch M and Bieth JG: Influence of elastin on the inhibition of
leucocyte elastase by alpha 1-proteinase inhibitor and bron-
chial inhibitor. Potent inhibition of elastin-bound elastase by
bronchial inhibitor. Biochem J 1986, 238:269-73.
32. Ohlsson K: Interactions between granulocyte proteases and
protease inhibitors in the lung. Bull Eur Physiopathol Respir 1980,
16:209-22.
33. Abbinante-Nissen JM, Simpson LG and Leikauf GD: Neutrophil
elastase increases secretory leukocyte protease inhibitor
transcript levels in airway epithelial cells. Am J Physiol 1993,
265:L286-92.
34. Sallenave JM, Shulmann J, Crossley J, Jordana M and Gauldie J: Regu-
lation of secretory leukocyte proteinase inhibitor (SLPI) and
elastase-specific inhibitor (ESI/elafin) in human airway epi-
thelial cells by cytokines and neutrophilic enzymes. Am J Respir
Cell Mol Biol 1994, 11:733-41.
35. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF,
Wright CD, Weyant MJ, Hydo L, Reeves F, Shiloh MU and Ding A:
Secretory leukocyte protease inhibitor, an inhibitor of neu-
trophil activation, is elevated in serum in human sepsis and
experimental endotoxemia. Crit Care Med 2000, 28:1276-82.
36. Abbinante-Nissen JM, Simpson LG and Leikauf GD: Corticosteroids
increase secretory leukocyte protease inhibitor transcript
levels in airway epithelial cells. Am J Physiol 1995, 268:L601-6.
37. van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer
WI, Kuijpers AL, Schalkwijk J and Hiemstra PS: Regulation of SLPI
and elafin release from bronchial epithelial cells by neu-
trophil defensins. Am J Physiol Lung Cell Mol Physiol 2000, 278:L51-8.
38. Ochnio JJ, Abboud RT, Lam S, Johal SS, Smith CJ and Johnson DA:
Bronchial leukocyte proteinase inhibitor levels in bronchial
washings in asthma patients. Chest 1988, 93:1008-12.
39. Westin U, Lundberg E, Wihl JA and Ohlsson K: The effect of
immediate-hypersensitivity reactions on the level of SLPI,
granulocyte elastase, alpha1-antitrypsin, and albumin in
nasal secretions, by the method of unilateral antigen
challenge. Allergy 1999, 54:857-64.
40. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang
SK, Bieber J and Chi DS: The human mast cell: functions in phys-
iology and disease. Front Biosci 2001, 6:D1109-27.
41. Bradding P and Holgate ST: The mast cell as a source of
cytokines in asthma. Ann N Y Acad Sci 1996, 796:272-81.
42. Bradding P and Holgate ST: Immunopathology and human mast
cell cytokines. Crit Rev Oncol Hematol 1999, 31:119-33.
43. Anderson DF, Zhang S, Bradding P, McGill JI, Holgate ST and Roche
WR: The relative contribution of mast cell subsets to con-
junctival TH2-like cytokines.  Invest Ophthalmol Vis Sci 2001,
42:995-1001.
44. Church MK and Cauldfield JP: Mast cells and basophil functions.
In: Allery Edited by: Holgate ST, Church MK. Gover Medical Publishing;
1993:5.1-5.12. 
45. Dietze SC, Sommerhoff CP and Fritz H: Inhibition of histamine
release from human mast cells ex vivo by natural and syn-
thetic chymase inhibitors.  Biol Chem Hoppe Seyler 1990,
371(Suppl):75-9.
46. Westin U, Lundberg E and Ohlsson K: IgE-mediated histamine
release from nasal mucosa is inhibited by SLPI (secretory
leukocyte protease inhibitor) to the level of spontaneous
release. Mediators Inflamm 1998, 7:217-20.
47. Westin U, Polling A, Ljungkrantz I and Ohlsson K: Identification of
SLPI (secretory leukocyte protease inhibitor) in human
mast cells using immunohistochemistry and in situ
hybridisation. Biol Chem 1999, 380:489-93.
48. Hill AT, Bayley D and Stockley RA: The interrelationship of spu-
tum inflammatory markers in patients with chronic
bronchitis. Am J Respir Crit Care Med 1999, 160:893-8.
49. Pierce JA, Jeppsson JO and Laurell CB: alpha-1 Antitrypsin pheno-
types determined by isoelectric focusing of the cysteine-anti-
trypsin mixed disulfide in serum. Anal Biochem 1976, 74:227-41.
50. Sigsgaard T, Brandslund L, Omland O, Hjort C, Lund ED, Pedersen
OF and MR Miller: S and Z alpha1-antitrypsin alleles are risk
factors for bronchial hyperresponsiveness in young farmers:
an example of gene/environment interaction. Eur Respir J 2000,
16:50-5.
51. Chaughey GH: The structure and airway biology of mast cell
proteinases. Am J Resoir Cell Mol Biol 1991, 4:387-394.
52. Nilsson G and Metcalf DD: Contemporary issues in mast cell
biology. Allergy and Asthma Proc 1990, 17:59-63.
53. Trautmann A, Feuerstein B, Ernst N, Brocker EB and Klein CE: Het-
erotypic cell-cell adhesion of human mast cells to fibroblasts.
Arch Dermatol Res 1997, 289:194-203.
54. Kruger-Krasagakes S, Grutzkau A, Baghramian B and Henz BM:
Interactions of immature human mast cells with extracellu-
lar matrix: expression of specific adhesion receptors and
their role in cell binding to matrix proteins. J Invest Dermatol
1996, 106:538-43.
55. Weber S, Babina M, Feller G and Henz BM: Human leukaemic
(HMC-1) and normal skin mast cells express beta 2-
integrins: characterization of beta 2-integrins and ICAM-1
on HMC-1 cells. Scand J Immunol 1997, 45:471-81.
56. Olsson N, Piek E, ten Dijke P and Nilsson G: Human mast cell
migration in response to members of the transforming
growth factor-beta family. J Leukoc Biol 2000, 67:350-6.
57. Turner H and Kinet JP: Signalling through the high-affinity IgE
receptor Fc epsilonRI. Nature 1999, 402:B24-30.
58. Miller HD and Pemberton AD: Tissue-specific expression of
mast cell granule serine proteinases and their role in inflam-
mation in the lung and gut. Immunology 2002, 04:375-390.
59. Butterfield JH, Weiler D, Dewald G and Gleich GJ: Establishment
of an immature mast cell line from a patient with mast cell
leukemia. Leuk Res 1988, 12:345-355.
60. Chomczynski P and Sacchi N: Single-step method of RNA isola-
tion by acid guanidinium thiocyanate-phenol-chloroform
extraction. Anal Biochem 1987, 162:156-9.